Stock Analysis
Twist Bioscience Corporation Common StockTWST
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy16 analystsPrice is 60% of the way from the year's low to its high.
Cash covers 154% of debt · Q3 2026.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health75
Risks
- Valuation20
- Profitability0
Weak fundamentals at a demanding price.
Market context
-8.1% today· Z 1.4σ
Bull Case
- ✓Altman Z 18.7 — safe-zone balance sheet
- ✓Revenue CAGR 29.9% — durable top-line growth
What's happening with TWST
Profile
Strong financial health; profitability, moat, valuation, growth and earnings quality lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-1.1%)0/25
- P/S (20.1x)0/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (29.9%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-29.6%)0/25
- ROE (-30.7%)0/25
- Net margin (-31.7%)0/25
- Operating margin (-33.6%)0/25
- Financial Health75/100 · Strong
- Altman Z (18.72)25/25
- Current ratio (2.67)25/25
- Interest coverage (-43431.8x)0/25
- Net cash / debt (Net cash)25/25
- Quality35/100 · Weak
- Piotroski F (4/9)10/25
- Beneish M (-2.67)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 69.9%)0/25
- Moat13/100 · Weak
- ROIC >12% years (0/7 yrs)0/25
- Median gross margin (39.1%)13/25
- FCF-positive years (0/7 yrs)0/25
- Worst-year net margin (worst -198.0%)0/25
Risk Flags
- ⚠Negative FCF margin (-0.2%) — burning cash
- ⚠SBC 15.4% of revenue — real dilution cost
- ⚠7 loss-making years in recent history
- ⚠Interest coverage -43431.8× — thin debt cushion
About Twist Bioscience Corporation Common Stock
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Show more
The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Headquarters: SOUTH SAN FRANCISCO, CA · Employees: 979 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-1.1%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -32.6%–-0.7% · 97th pct
P/S (TTM)20.13xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 2.9x–31.5x · 97th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales22.1xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio19.50xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-1.22A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-29.6%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-30.7%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-20.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-31.7%D
Grade D: LowNet Income / Revenue
Operating Margin-33.6%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin52.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-21.6%D
Grade D: LowFCF / Revenue
True FCF Margin-37.0%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR29.9%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue15.4%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score18.72A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.67xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.30xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-43431.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.4xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.24xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.54xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
35DPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.67A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability69.9%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue9.3%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.66xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Laponis Adam Filed | Laponis Adam | SellOpen market sale | -2462 | |
Leproust Emily M. Filed | Leproust Emily M. | SellOpen market sale | -45 | |
Leproust Emily M. Filed | Leproust Emily M. | SellOpen market sale | -146 | |
Leproust Emily M. Filed | Leproust Emily M. | SellOpen market sale | -297 | |
Leproust Emily M. Filed | Leproust Emily M. | SellOpen market sale | -290 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Leproust Emily M. Filed | Leproust Emily M. | SellOpen market sale | -432 | |
Leproust Emily M. Filed | Leproust Emily M. | SellOpen market sale | -1017 | |
Leproust Emily M. Filed | Leproust Emily M. | SellOpen market sale | -481 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
13EROIC >12% Years0/7 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)39.1%C
Grade C: ModerateMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/7 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-198.0%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$2.66
Cash & short-term investments per share (Finnhub)
Book Value / Share$7.11
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$108.59M
Total debt obligations (short + long term)
Cash & Equiv.$166.84M
Cash and short-term investments
Net Debt$-58.25MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$445.74M
Shareholders' equity (book value)
Asset / Liability2.97xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$8.69B
Current Market Capitalization
Beta2.17D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Twist Bioscience Corporation Common Stock (TWST)
TWST is down 8.13% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for Twist Bioscience Corporation Common Stock. Altman Z-Score of 18.72 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.67 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 30% annually — a strong growth profile.
- Free-cash-flow margin is negative (-22%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -43431.8× leaves little room for earnings shocks.
- Twist Bioscience Corporation Common Stock posted a net loss in 7 of 7 available completed fiscal years (2019–2025).
- At a valuation score of 20/100, TWST trades at a premium to its historical multiples.
See how TWST ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TWST moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 6 | Regular | 168.58 | -17.77% | -4.57 |
| Oct 6 | After-hours | 167.33 | -18.37% | -4.72 |
| Sep 24 | Regular | 182.89 | +15.39% | 3.44 |
| Sep 24 | After-hours | 184.05 | +16.12% | 3.59 |
Frequently Asked Questions about TWST
What is the current Twist Bioscience Corporation Common Stock (TWST) stock price?
TWST is trading at $132.75 at the last market close, down 8.13% on the session. PreMarketPrice tracks TWST pre-market, intraday and after-hours prices.
Is TWST stock a buy right now?
PreMarketPrice's quantitative model rates Twist Bioscience Corporation Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TWST stock overvalued?
Twist Bioscience Corporation Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Twist Bioscience Corporation Common Stock report earnings?
No confirmed earnings date is currently scheduled for TWST. The Earnings section lists recent reports and updates as dates are announced.
What sector does Twist Bioscience Corporation Common Stock operate in?
Twist Bioscience Corporation Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Twist Bioscience Corporation Common Stock do?
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
About Twist Bioscience Corporation Common Stock (TWST) Stock
Twist Bioscience Corporation Common Stock (TWST) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Twist Bioscience Corporation Common Stock is trading at $132.75, down 8.13% on the day with a market capitalization of $8.7 billion. The financial health score for TWST is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TWST stock.
TWST Stock Analysis & Key Metrics
On PreMarketPrice, you can track Twist Bioscience Corporation Common Stock (TWST) across multiple dimensions:
- Pre-market price & movement: Real-time TWST stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TWST with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Twist Bioscience Corporation Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TWST.
- Sector peers: Compare TWST against 5 other healthcare stocks on key financial metrics.
Is TWST a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Twist Bioscience Corporation Common Stock (TWST) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Twist Bioscience Corporation Common Stock (TWST) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.